Conference Call with Jubilant Pharmova Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Jubilant Pharmova declares Q3FY22 result: Revenue was at Rs 1,311 Crore versus Rs 1,771 Crore in Q3'FY21 Reported EBITDA at Rs 200 Crore versus Rs 496 Crore in Q3'FY21 Finance costs at Rs 37 Crore vs. Rs 46 Crore in Q3'FY21 Effective Tax Rate of 27.7% vs. 35.6% in Q3’FY21. Current quarter benefited from reversal of certain deferred tax liabilities. PAT was at Rs 51 Crore as compared with Rs 219 Crore in Q3'FY21 EPS is Rs 3.2 versus Rs 13.75 in Q3'FY21 Capital expenditure for the quarter was Rs 112 Crore Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “The Company’s performance during the quarter was affected by headwinds witnessed in Pharmaceuticals segment, which was partly mitigated by continued robust performance in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while the Radiopharma business witnessed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market. Tapering of COVID related opportunities led to lower revenue and profitability in the CMO business. API business was affected due to lower volumes resulting from an unplanned plant shutdown during the quarter. Performance of API business expected to normalize in Q4’FY22. In our Contract Research and Development Services business, we continue to witness strong growth on a YoY basis driven by robust demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our lead program – LSD1/HDAC6 inhibitor has successfully received FDA clearance for IND filing and is on track for initiation of Phase 1 trials in Q4’FY22. Additional IND filings for pipeline programs to follow in FY 23. I would like to mention that over the medium term, we have strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.” Result PDF
Conference Call with Jubilant Pharmova Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Highlights Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21 Reported EBITDA at Rs 344 Crore versus Rs 353 Crore in Q2'FY21 Finance costs at Rs 35 Crore vs. Rs 46 Crore in Q2'FY21 PAT was at Rs 143 Crore as compared with Rs 147 Crore in Q2'FY21 EPS is Rs 8.97 versus Rs 9.21 in Q2'FY21 Capital expenditure for the quarter was Rs 131 Crore Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said: “The Company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while Radiopharma, Allergy and CMO businesses reported growth on a YoY basis, the API business’ performance was lower on a higher base last year and Generics business witnessed headwinds due to temporary pricing pressure in the US market. The Generics business was also affected during the quarter by the Import Alert at the Roorkee plant and by impact of the Industry wide impurity issue in certain sartan products that led to lower sales and some product withdrawal. In our Contract Research and Development Services business, we witnessed strong growth both YoY and sequentially driven by continued strong demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our plans are on track to take one program to the clinical stage by end of this financial year. During H1’FY22, we grew our revenues by 20% YoY and improved our EBITDA margins by 2.44% vs. H1’FY21 due to recovery in Radiopharma business and strong performance in Allergy Immunotherapy, CMO, API and Contract Research businesses. I would like to mention that over the medium term, we have very strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.” Result PDF